← 홈

Antibody · 폐암 (NSCLC)

82개 · ADC 1068 · Antibody 5456 · CGT 2744 · 다음 갱신 D-13 · 마지막 7월 13일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 82개
AntibodyCHotXin-Hua XuPhase 2

AK104 (Cadonilimab, Cadonilimab (AK104))

Non-small Cell Lung Cancer · Leptomeningeal Metastasis

#LeptomeningealMetastasis#Antibody#Phase2#인기#항체+5
임상시험 101상태 RECRUITING
AntibodyCEli Lilly and CompanyDeruxtecan]Phase 3

Ramucirumab (Ramucirumab)

Advanced Esophageal Adenocarcinoma; Advanced Gastric Adenocarcinoma · Non-Small Cell Lung Cancer

#Non-SmallCellLungCancer#Antibody#Phase3#인기#항체+5
효능 ORR 40%임상시험 86상태 RECRUITING
AntibodyMerckvedotin after avelumabPhase 1

pembrolizumab (Keytruda, Pembrolizumab (+) Berahyaluronidase alfa)

Advanced or Metastatic Solid Tumors · Metastatic Non-small Cell Lung Cancer

#MetastaticNon-smallCellLungCance#Antibody#Phase1#인기#항체+5
효능 ORR 65.1%임상시험 63상태 ACTIVE
AntibodyRochegovitecan in patients with …Preclinical

MPDL3280A (Atezolizumab, Atezolizumab (MPDL3280A))

Non-Small Cell Lung Cancer · Non-Small Cell Lung Cancer

#Non-SmallCellLungCancer#Antibody#Preclinical#인기#항체+4
효능 ORR 46.4%임상시험 60상태 ACTIVE
AntibodyRocheatApproved

bevacizumab [Avastin] (bevacizumab [Avastin])

Non-Squamous Non-Small Cell Lung Cancer · Pancreatic Cancer

#PancreaticCancer#Antibody#Approved#항체#면역항체+5
효능 ORR 83%임상시험 43상태 ACTIVE
AntibodystaleAstraZenecaPhase 2

Oleclumab (Oleclumab)

Non-small Cell Lung Cancer · Non-Small Cell Lung Cancer

#Non-SmallCellLungCancer#Antibody#Phase2#항체#면역항체+3
효능 ORR 56.5%임상시험 28상태 RECRUITING
AntibodystaleImmunityBio, Inc.Phase 2

Necitumumab (Necitumumab)

Squamous Cell Carcinoma · Non-Small Cell Lung Cancer

#Non-SmallCellLungCancer#Antibody#Phase2#항체#면역항체+3
효능 ORR 76%임상시험 23상태 DISCONTINUED
AntibodystalePfizerPhase 1

sasanlimab (sasanlimab)

Carcinoma, Pancreatic Ductal; Colorectal Neoplasms · Non-small Cell Lung Cancer

#Non-smallCellLungCancer#Antibody#Phase1#항체#면역항체+5
효능 ORR 33.3%임상시험 23상태 DISCONTINUED
AntibodystaleAstraZenecaPhase 2

Monalizumab (Monalizumab)

Non-small Cell Lung Cancer · Non-small Cell Lung Cancer

#Non-smallCellLungCancer#Antibody#Phase2#항체#면역항체+2
효능 ORR 23.9%임상시험 22상태 RECRUITING
AntibodystaleMerckPhase 3

pembrolizumab (Keytruda, Pembrolizumab [KEYTRUDA®])

Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) · Metastatic Cancer

#MetastaticCancer#Antibody#Phase3#항체#면역항체+4
효능 ORR 40%임상시험 22상태 DISCONTINUED
AntibodystaleAstraZenecaPhase 3

MEDI4736 (Durvalumab, Durvalumab (MEDI4736))

Non-small Cell Lung Cancer · Non Small Cell Lung Carcinoma NSCLC

#NonSmallCellLungCarcinomaNSCLC#Antibody#Phase3#항체#면역항체+3
효능 ORR 44%임상시험 7상태 RECRUITING
AntibodystalePeregrine PharmaceuticalsPhase 2

bavituximab (bavituximab)

Non-Small Cell Lung Cancer · Non-Small Cell Lung Cancer

#Non-SmallCellLungCancer#Antibody#Phase2#항체#면역항체+2
효능 ORR 9%임상시험 4상태 ACTIVE
AntibodystaleAbbViePhase 1

Cofetuzumab Pelidotin (Cofetuzumab Pelidotin)

Cancer; Non-small Cell Lung Cancer (NSCLC) · Cancer

#Cancer#Antibody#Phase1#항체#면역항체+3
임상시험 2상태 DISCONTINUED
AntibodystaleEli Lilly and CompanyPhase 2

cixutumumab (IMC-A12, IMC-A12 (cixutumumab))

Non-Small Cell Lung Cancer · Colon Cancer

#ColonCancer#Antibody#Phase2#항체#면역항체+3
효능 ORR 37.9%임상시험 2상태 ACTIVE
AntibodystaleJeffrey ClarkePhase 1

AMG 479, Everolimus, Panitumumab (AMG 479, Everolimus, Panitumumab)

Advanced Solid Tumors, Non-small Cell Lung Cancer · Advanced Solid Tumors, Non-small Cell Lu

#AdvancedSolidTumorsNon-smallCell#Antibody#Phase1#항체#면역항체+4
임상시험 1상태 ACTIVE
AntibodystaleSidney Kimmel Comprehensive Can…Phase 2

nivolumab (Opdivo, Adagrasib/Nivolumab)

Resectable Non-Small Cell Lung Cancer · Resectable Non-Small Cell Lung Cancer

#ResectableNon-SmallCellLungCance#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 DISCONTINUED
AntibodystaleRochePhase 2

Adebrelimab Combined With Bevacizumab and Albumin Paclitaxel (Adebrelimab Combined With Bevacizumab and Albumin Paclitaxel)

Non-small Cell Lung Cancer · Non-small Cell Lung Cancer

#Non-smallCellLungCancer#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleThe First Affiliated Hospital o…Phase 2

Adebrelimab Combined with Bevacizumab and Docetaxel (Adebrelimab Combined with Bevacizumab and Docetaxel)

Non-small Cell Lung Cancer · Non-small Cell Lung Cancer

#Non-smallCellLungCancer#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleKymab LimitedPhase 2

Alomfilimab (Alomfilimab)

Squamous Cell Carcinoma of Head and Neck; Non-small Cell Lung Cancer · Squamous Cell Carcinoma of Head and Neck

#SquamousCellCarcinomaofHeadandNe#Antibody#Phase2#항체#면역항체+3
효능 ORR 0%임상시험 1상태 DISCONTINUED
AntibodystaleRochePhase 3

Bevacizumab + Pemetrexed (Bevacizumab + Pemetrexed)

Non-squamous Non-small Cell Lung Cancer · Non-squamous Non-small Cell Lung Cancer

#Non-squamousNon-smallCellLungCan#Antibody#Phase3#항체#면역항체+2
임상시험 1상태 ACTIVE

1 / 5 페이지

← 이전다음 →